Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
Heart failure affects an estimated 64.3 million people worldwide
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
The study will run across 18 sites and enroll roughly 200 patients over 24 months
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
